tiprankstipranks
NeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1
PremiumCompany AnnouncementsNeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1
2M ago
NeuroBo Pharmaceuticals announces data from SAD Part 1 of trial of DA-1726
Premium
The Fly
NeuroBo Pharmaceuticals announces data from SAD Part 1 of trial of DA-1726
2M ago
NeuroBo Pharmaceuticals reports Q2 EPS ($1.85), consensus ($1.12)
Premium
The Fly
NeuroBo Pharmaceuticals reports Q2 EPS ($1.85), consensus ($1.12)
3M ago
NeuroBo Pharmaceuticals signs research agreement for obesity treatment
PremiumThe FlyNeuroBo Pharmaceuticals signs research agreement for obesity treatment
4M ago
NeuroBo Pharmaceuticals Strikes Licensing Deal for NB-01
Premium
Company Announcements
NeuroBo Pharmaceuticals Strikes Licensing Deal for NB-01
4M ago
NeuroBo Pharmaceuticals announces license agreement with MThera Pharma
Premium
The Fly
NeuroBo Pharmaceuticals announces license agreement with MThera Pharma
4M ago
NeuroBo Pharmaceuticals’ DA-1726 demonstrates ‘superiority in weight loss’
PremiumThe FlyNeuroBo Pharmaceuticals’ DA-1726 demonstrates ‘superiority in weight loss’
5M ago
NeuroBo Pharmaceuticals Enhances Equity Plan and Elects Directors
Premium
Company Announcements
NeuroBo Pharmaceuticals Enhances Equity Plan and Elects Directors
6M ago
NeuroBo to report pre-clinical data on DA-1241 at EASL Congress 2024
Premium
The Fly
NeuroBo to report pre-clinical data on DA-1241 at EASL Congress 2024
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100